Darolutamide in Combination with ADT and Docetaxel in Patients with #mHSPC: Real-World Evidence from the SOGUG-TRIDA Study of the Spanish Oncology Genitourinary Group. Presented by

UroToday.com· @urotoday · X·2026-10-23 22:45· 2 天前评分45

正文 · 原文

Darolutamide in Combination with ADT and Docetaxel in Patients with #mHSPC: Real-World Evidence from the SOGUG-TRIDA Study of the Spanish Oncology Genitourinary Group. Presented by Dr. Ricardo Sanchez-Escribano Morcuende, #ESMO26 written coverage by @zklaassen_md > https://bit.ly/3Ws6aih @sogug1 @myESMO

245 浏览 · 3 赞 · 2 转发 · 0 回复

会议摘要

2300TIPNCT07365995 NCT07365995 NCT07365995按 Metastatic prostate cancer 对上

BNT324-03: A phase 3, randomized, open-label trial comparing elfetabart drozuntecan, a B7H3 antibody-drug conjugate, with investigator's choice of docetaxel or cabazitaxel in patients with metastatic castration-resistant prostate cancer

https://esmocongress.esmo.org

LBA15按 Proffered paper 2: Breast cancer, early and advanced stage 对上

Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study

https://esmocongress.esmo.org

NCT04884282NCT04884282按 - **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) 对上

- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

https://esmocongress.esmo.org

来源：UroToday.com · x.com